Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn’s disease-Reference-Cited by-同舟云学术

Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn’s disease

Published:2020-09-10 Issue: Volume: Page:
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Townsend Tristan¹,Razanskaite Violeta²,Dodd Susanna³,Storey Daniel¹,Michail Stephanie¹,Morgan James¹,Davies Michael¹,Penman Douglas⁴,Watters Christopher⁴,Swaminathan Mira⁵,Sabine Joseph⁴,Chapman Adam²,Smith Philip J¹,Flanagan Paul K.⁴,Reilly Ian⁵,Bodger Keith³^ORCID,Subramanian Sreedhar¹^ORCID

Affiliation:

1. Department of Gastroenterology; Royal Liverpool University Hospital; Liverpool UK

2. Department of Gastroenterology; University Hospital Aintree; Liverpool UK

3. Department of Biostatistics; Institute of Translational Medicine; University of Liverpool; Liverpool UK

4. Department of Gastroenterology; Wirral University Teaching Hospital; Wirral UK

5. Department of Gastroenterology; Countess of Chester Hospital; Chester UK

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.16057/fullpdf

Reference26 articles.

1. Loss of response to anti-TNFs: definition, epidemiology, and management;Roda;Clin Transl Gastroenterol,2016

2. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed;Sands;Gastroenterology,2014

3. Ustekinumab as induction and maintenance therapy for Crohn's disease;Feagan;N Engl J Med,2016

4. Ustekinumab induction and maintenance therapy in refractory Crohn's disease;Sandborn;N Engl J Med,2012

5. Effectiveness of ustekinumab and vedolizumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor: a multi-centre comparative study;Alric;J Crohns Colitis,2020

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn’s disease patients: a retrospective multicenter study;BMC Gastroenterology;2024-09-11

2. Saudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents;Saudi Journal of Gastroenterology;2024-08-30

3. How comparative studies can inform treatment decisions for Crohn’s disease;Expert Opinion on Biological Therapy;2024-08-12

4. Vedolizumab versus ustekinumab in Crohn’s disease with prior anti-tumor necrosis factor failure: an updated meta-analysis;European Journal of Gastroenterology & Hepatology;2024-07-02

5. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA;Pharmaceutics;2024-05-08